2,351 results on '"Vermeire S"'
Search Results
202. Recognition of anatomical predilection sites in canine elbow pathology on bone scans using micro-single photon emission tomography
203. A145 EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY
204. Hydrated Nucleus Pulposus Extrusion in Dogs: Thoracolumbar Compared to Cervical Cases
205. DOP79 Biomarkers for IBD using OLINK Proteomics inflammation panel: Preliminary results from the COLLIBRI consortium
206. OP19 Classifying perianal fistulising Crohn’s Disease: An expert-consensus to guide decision-making in daily practice and clinical trials
207. DOP17 Evaluating segmental healing with the modified Mayo endoscopic score (MMES) has a clear additional value in predicting long-term outcome in patients with Ulcerative Colitis: Results from a prospective cohort study
208. DOP37 Efficacy and safety of filgotinib in patients with Ulcerative Colitis stratified by age: Post hoc analysis of the phase 2b/3 SELECTION and SELECTIONLTE studies
209. DOP41 Efficacy and safety of extended induction treatment with upadacitinib 45 mg once daily followed by maintenance upadacitinib 15 or 30 mg once daily in patients with moderately to severely active Ulcerative Colitis
210. DOP89 Infliximab and ustekinumab clearance during induction predicts post-induction endoscopic outcomes in patients with Crohn’s Disease
211. P082 The profibrogenic role of neutrophil extracellular traps in stenotic Crohn’s disease: a new antifibrotic target?
212. DOP81 Baseline whole-blood gene expression of TREM1 does not predict clinical or endoscopic outcomes following adalimumab treatment in patients with Ulcerative Colitis or Crohn’s Disease in the SERENE studies
213. P475 Profiling the use of Complementary Alternative Medicines among IBD patients
214. P073 Eosinophil depletion partially protects from colonic inflammation, but increases colonic collagen deposition in a DSS colitis model
215. P401 Tofacitinib tissue exposure correlates with endoscopic outcome
216. P030 Distinct molecular profiles between idiopathic cryptoglandular and Crohn-related perianal fistulas
217. P533 Predictors of sustained remission after infliximab de-escalation in patients with inflammatory bowel diseases
218. P257 The clinical decision support tool has low performance in predicting outcome to ustekinumab in Crohn’s disease
219. P447 Positioning of ustekinumab affects its effectiveness, drug persistence and serum exposure in Crohn’s disease
220. OP28 A randomized placebo controlled clinical trial with 5-hydroxytryptophan in patients with quiescent Inflammatory Bowel Disease and fatigue (Trp-IBD)
221. POSA350 Effect of Filgotinib on EQ-5D-5L and Work Productivity and Activity Impairment Among Patients with Ulcerative Colitis: Results from the Phase 2B/3 Selection Trial
222. N18 Introduction of inflammatory bowel disease specialized dietitian and nutritional status in a multidisciplinary IBD team
223. P517 Re-treatment with filgotinib in patients with Ulcerative Colitis following treatment interruption: Analysis of the SELECTION and SELECTIONLTE studies
224. P591 Biological therapies and small molecules show to be efficacious in patients with moderate-to-severe ulcerative proctitis
225. P529 Evolution of COVID19 serology in a real-life population of IMID patients. Results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID)
226. DOP90 Efficacy of the treat-to-target approach in modifying disease course with ustekinumab in patients with moderate-to-severe Crohn’s Disease: Results from the STARDUST trial
227. OP34 Efficacy and safety of advanced induction and maintenance therapies in patients with moderately to severely active Ulcerative Colitis: An indirect treatment comparison using Bayesian network meta-analysis
228. P004 Microbiota, not host origin drives ex vivo epithelial response in ulcerative colitis patients and non-IBD controls
229. P286 Sustained improvement in health-related quality of life outcomes in patients with Ulcerative Colitis with long-term tofacitinib treatment in the open-label extension study, OCTAVE Open
230. OP30 Upadacitinib modulates inflammatory pathways in gut tissue in patients with Ulcerative Colitis: Transcriptomic profiling from the Phase 2b study, U-ACHIEVE
231. P576 Real-world effectiveness and safety of risankizumab in patients with moderate-to-severe multi-refractory Crohn’s disease: a Belgian multi-centric cohort study
232. P442 Real-world endoscopic and histologic outcomes are linked to ustekinumab exposure in Ulcerative Colitis
233. P041 Characterization of cytokine and drug concentrations in serum, mucosa and faeces during induction treatment of moderate-to-severe ulcerative colitis with anti-TNF monoclonal antibodies
234. OP07 Exploring disease control by combining clinical, biological, and health-related quality of life remission with endoscopic improvements among Ulcerative Colitis patients treated with filgotinib: A post-hoc analysis from the SELECTION trial
235. P115 Implementation of a vaccination tool in the electronic patient health record significantly increases vaccination coverage
236. P662 Colorectal Cancer in Patients with Ulcerative Colitis: A National Cohort Study between 1991–2020
237. P333 Precise and unbiased infliximab dosing in patients with inflammatory bowel diseases using a multi-model averaging approach
238. P370 Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from, 52-week phase, 3 study U ACHIEVE maintenance
239. P095 Anti-inflammatory effect of high acetate concentration on organoid-derived epithelial monolayer from patients with Ulcerative Colitis
240. DOP38 Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1
241. OP03 Standardized faecal microbiota transplantation with microbiome-guided donor selection in active UC patients: A randomized, placebo-controlled intervention study
242. P441 Adalimumab versus ustekinumab as first-line biological in a real-life cohort of moderate-to-severe Crohn’s disease
243. P496 Efficacy and safety of ustekinumab for chronic antibiotic refractory pouchitis: A Belgian open-label multicentre pilot study
244. N01 Type of patient education impacts the willingness to switch from an IV to SC of a biological in patients with Inflammatory Bowel Disease: A multicentre, comparative study
245. P342 Trans-continental analysis of over, 2000 Inflammatory Bowel Disease patients implicates geography, disease type, and exposure to immunosuppression as drivers of SARS-CoV-2 seroprevalence: data from the ICARUS-IBD Consortium
246. Modified Side-To-Side Isoperistaltic Strictureplasty over the Ileocaecal Valve: An Alternative to Ileocaecal Resection in Extensive Terminal Ileal Crohn’s Disease
247. Patients with large-duct primary sclerosing cholangitis and Crohnʼs disease have a better outcome than those with ulcerative colitis, or without IBD
248. Therapeutic innovations in inflammatory bowel diseases
249. Magnetic resonance enterography is feasible and reliable in multicenter clinical trials in patients with Crohnʼs disease, and may help select subjects with active inflammation
250. Smoking behaviour and knowledge of the health effects of smoking in patients with inflammatory bowel disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.